Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

sections

Drug efficacy

Olaparib halts tumour growth in advanced prostate cancer

Oolaparib, a drug approved for the treatment of women with ovarian cancer who have inherited BRCA mutations, also benefits men with prostate cancer. In the image, prostate cancer cells

Source: Wikimedia Commons

In a phase II clinical trial, of 15 men with prostate cancer that had detectable DNA repair mutations, 13 responded to olaparib

Olaparib was approved by the US Food and Drug Administration in December 2014 for the treatment of women with ovarian cancer who have inherited BRCA mutations.

Now, researchers have shown that the drug also benefits men with prostate cancer.

In a phase II clinical trial, 16 of 49 patients with treatment-resistant advanced prostate cancer responded to olaparib. Of 15 men with detectable DNA repair mutations, 13 responded to olaparib, according to research[1] reported at the American Association of Cancer Research conference in Philadelphia on 21 April 2015.

The investigators, led by a team from the Institute of Cancer Research and the Royal Marsden NHS Trust, London, now plan to test the drug exclusively in men with prostate cancer that has detectable DNA repair mutations. 

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20068443

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • FASTtrack: Pharmacology

    FASTtrack: Pharmacology

    FASTtrack: Pharmacology is a study guide providing an account of drug action, as well as dealing with molecular pharmacology at a more advanced level.

    £28.00Buy now
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.